Literature DB >> 2850042

Quantification of dideoxycytidine in human plasma by gas chromatography/mass spectrometry.

F R Rubio1, T Crews, W A Garland, E K Fukuda.   

Abstract

A gas chromatographic/mass spectrometric procedure has been developed for the quantification in plasma of dideoxycytidine (DDC), a candidate anti-AIDS drug. The assay uses an extraction with ethyl acetate containing 10% methanol followed by three derivatization steps: (i) reaction with t-butyl dimethyl chlorosilane to silylate the 5'-hydroxyl group; (ii) pentafluorobenzoylation of the amino group with pentafluorobenzoyl chloride; (iii) methylation of the ring nitrogen adjacent to the amino group with diazomethane. The resulting derivative is quantified using stable isotope dilution, selective ion monitoring and methane negative chemical ionization mass spectrometry. Plasma concentrations of DDC were measured over a range of 2-200 ng ml-1 using 1 ml plasma for extraction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850042     DOI: 10.1002/bms.1200170509

Source DB:  PubMed          Journal:  Biomed Environ Mass Spectrom        ISSN: 0887-6134


  7 in total

Review 1.  Problems in pharmacokinetic investigations in patients with HIV infection.

Authors:  J D Unadkat; J M Agosti
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients.

Authors:  J W Massarella; L A Nazareno; S Passe; B Min
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

4.  The effect of food on pharmacokinetics of zalcitabine in HIV-positive patients.

Authors:  L A Nazareno; A A Holazo; R Limjuco; S Passe; S K Twardy; B Min; J W Massarella
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

5.  Zalcitabine population pharmacokinetics: application of radioimmunoassay.

Authors:  J M Adams; M J Shelton; R G Hewitt; M DeRemer; R DiFrancesco; T H Grasela; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.

Authors:  D M Burger; H Rosing; C H ten Napel; T Duyts; P L Meenhorst; J W Mulder; C H Koks; A Bult; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 7.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.